Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

Condition:   HNSCC
Interventions:   Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA];   Other: adjuvant radiochemotherapy
Sponsor:   University of Leipzig
Not yet recruiting

https://ift.tt/2GVMpVn